NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2015
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
[ see Clinical Pharmacology ( ) ].
Indications (22)
the following infections caused by designated susceptible Gram-negative microorganisms in adultused in combination with metronidazole ( ) Complicated Urinary Tract Infections (cUTI)including Pyelonephritis ( ) Hospital-acquired Bacterial PneumoniaVentilator-associated Bacterial Pneumonia (HABP/VABP) ( ) To reduce the development of drug-resistant bacteriamaintain the effectiveness of AVYCAZother antibacterial drugsAVYCAZ should be used only to treatprevent infectionsstrongly suspected to be caused by susceptible bacteriacomplicated intra-abdominal infections (cIAI) in adultKlebsiella pneumoniaeProteus mirabilisEnterobacter cloacaeKlebsiella oxytocaCitrobacter freundii complexPseudomonas aeruginosacomplicated urinary tract infections (cUTI) including pyelonephritis in adulthospital-acquired bacterial pneumoniaventilator-associated bacterial pneumonia (HABP/VABP) in adultEscherichia coliSerratia marcescensHaemophilus influenzae
Loss of Exclusivity
LOE Date
Jun 15, 2032
76 months away
Patent Expiry
Jun 15, 2032
Exclusivity Expiry
Jan 26, 2027